

**Remarks**

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Thus, claim 2 has been amended in response to the Examiner's position as set forth in the Advisory Action mailed September 21, 2009.

That is, the definition for L has now been clarified.

Furthermore, the linkage properties of R<sub>4</sub> are now further clarified by adding "or polyvalent branched chain alkyl group" after "straight or branched chain alkylene group". This wording is based on the description in the specification at page 18, line 19 to page 19, line 10, which deals with a method of manufacture of substrates carrying more than one label, in particular "R<sub>4</sub> is a polyfunctional residue having two or more reactive [...] groups" (page 18, line 21), and "a branched residue R<sub>4</sub> carrying a plurality of labels" (page 19, line 4). Furthermore, Schemes 10 and 11 on pages 32-33 illustrate such polyvalent branched linkers R<sub>4</sub>.

The methotrexate moiety is now further characterized by "attached via a primary carboxy group" based on Schemes 15 and 16 and Examples 45 and 46.

The definition for R<sub>4</sub> in claim 29 has been amended in the same manner as in claim 2.

Applicants respectfully submit that all of the Examiner's concerns have now been addressed, and that the application is in condition for allowance. Such allowance is solicited.

Respectfully submitted,

Maik KINDERMANN et al.

By



---

Michael R. Davis

Registration No. 25,134

Attorney for Applicants

MRD/pth  
Washington, D.C. 20005-1503  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 9, 2009